Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xiufen Chen

Showing results (41-50 of 52) with videos related to

Pageof 6
Sort By:
The American Journal of Surgical Pathology|March 19, 2025
Histopathologic Grading of Residual Tumor Predicts Survival of Intrahepatic Cholangiocarcinoma Patients Treated With Neoadjuvant Therapy: Major Pathologic Response and Its Clinical SignificanceGaohua Wu, Xiufen Chen, Rongkui Luo, et al.
Immunity|May 26, 2022
Dendritic cells can prime anti-tumor CD8<sup>+</sup> T cell responses through major histocompatibility complex cross-dressingBrendan W MacNabb, Sravya Tumuluru, Xiufen Chen, et al.
Journal of Cellular Physiology|July 27, 2007
Induction of regulatory T cells by physiological level estrogenPing Tai, Junpeng Wang, Huali Jin, et al.
Matter|December 13, 2021
Antigen-Multimers: Specific, Sensitive, Precise, and Multifunctional High-Avidity CAR-Staining ReagentsYifei Hu, Guoshuai Cao, Xiufen Chen, et al.
Haematologica|October 5, 2019
Calreticulin exposure on malignant blasts correlates with improved natural killer cell-mediated cytotoxicity in acute myeloid leukemia patientsIva Truxova, Lenka Kasikova, Cyril Salek, et al.
Biorxiv : the Preprint Server for Biology|June 4, 2025
Low-Strength Type I Interferon Signaling Promotes CAR T-Cell Treatment EfficacyErting Tang, Yifei Hu, Guoshuai Cao, et al.
Journal for Immunotherapy of Cancer|June 26, 2023
TIGIT is a key inhibitory checkpoint receptor in lymphomaJames Godfrey, Xiufen Chen, Nicole Sunseri, et al.
Cancer Immunology Research|May 11, 2026
Low-Strength Type I Interferon Signaling Promotes CAR T Cell Treatment EfficacyErting Tang, Yifei Hu, Guoshuai Cao, et al.
Cancer Immunology Research|December 11, 2020
Oxidized Lipoproteins Promote Resistance to Cancer Immunotherapy Independent of Patient ObesityNiloufar Khojandi, Lindsey M Kuehm, Alexander Piening, et al.
Biorxiv : the Preprint Server for Biology|February 8, 2024
Integrative genomic analysis identifies unique immune environments associated with immunotherapy response in diffuse large B cell lymphomaSravya Tumuluru, James K Godfrey, Alan Cooper, et al.
Pageof 6

Showing results (41-50 of 52) with videos related to

Sort By:
Pageof 6
The American Journal of Surgical Pathology|March 19, 2025
Histopathologic Grading of Residual Tumor Predicts Survival of Intrahepatic Cholangiocarcinoma Patients Treated With Neoadjuvant Therapy: Major Pathologic Response and Its Clinical SignificanceGaohua Wu, Xiufen Chen, Rongkui Luo, et al.
Immunity|May 26, 2022
Dendritic cells can prime anti-tumor CD8<sup>+</sup> T cell responses through major histocompatibility complex cross-dressingBrendan W MacNabb, Sravya Tumuluru, Xiufen Chen, et al.
Journal of Cellular Physiology|July 27, 2007
Induction of regulatory T cells by physiological level estrogenPing Tai, Junpeng Wang, Huali Jin, et al.
Matter|December 13, 2021
Antigen-Multimers: Specific, Sensitive, Precise, and Multifunctional High-Avidity CAR-Staining ReagentsYifei Hu, Guoshuai Cao, Xiufen Chen, et al.
Haematologica|October 5, 2019
Calreticulin exposure on malignant blasts correlates with improved natural killer cell-mediated cytotoxicity in acute myeloid leukemia patientsIva Truxova, Lenka Kasikova, Cyril Salek, et al.
Biorxiv : the Preprint Server for Biology|June 4, 2025
Low-Strength Type I Interferon Signaling Promotes CAR T-Cell Treatment EfficacyErting Tang, Yifei Hu, Guoshuai Cao, et al.
Journal for Immunotherapy of Cancer|June 26, 2023
TIGIT is a key inhibitory checkpoint receptor in lymphomaJames Godfrey, Xiufen Chen, Nicole Sunseri, et al.
Cancer Immunology Research|May 11, 2026
Low-Strength Type I Interferon Signaling Promotes CAR T Cell Treatment EfficacyErting Tang, Yifei Hu, Guoshuai Cao, et al.
Cancer Immunology Research|December 11, 2020
Oxidized Lipoproteins Promote Resistance to Cancer Immunotherapy Independent of Patient ObesityNiloufar Khojandi, Lindsey M Kuehm, Alexander Piening, et al.
Biorxiv : the Preprint Server for Biology|February 8, 2024
Integrative genomic analysis identifies unique immune environments associated with immunotherapy response in diffuse large B cell lymphomaSravya Tumuluru, James K Godfrey, Alan Cooper, et al.
Pageof 6